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Background. Determining infarct size and myocardial salvage in patients with ST-segment
elevation myocardial infarction (STEMI) is important when assessing the efficacy of new
reperfusion strategies. We investigated whether rest 82Rb-PET myocardial perfusion imaging
can estimate area at risk, final infarct size, and myocardial salvage index when compared to
cardiac SPECT and magnetic resonance (CMR).
Methods. Twelve STEMI patients were injected with 99mTc-Sestamibi intravenously
immediate prior to reperfusion. SPECT, 82Rb-PET, and CMR imaging were performed post-
reperfusion and at a 3-month follow-up. An automated algorithm determined area at risk, final
infarct size, and hence myocardial salvage index.
Results. SPECT, CMR, and PET were performed 2.2 ± 0.5, 34 ± 8.5, and 32 ± 24.4 h after
reperfusion, respectively. Mean (± SD) area at risk were 35.2 ± 16.6%, 34.7 ± 11.3%, and
28.1 ± 16.1% of the left ventricle (LV) in SPECT, CMR, and PET, respectively, P 5 0.04 for
difference. Mean final infarct size estimates were 12.3 ± 15.4%, 13.7 ± 10.4%, and 11.9 ± 14.6%
of the LV in SPECT, CMR, and PET imaging, respectively, P 5 .72. Myocardial salvage indices
were 0.64 ± 0.33 (SPECT), 0.65 ± 0.20 (CMR), and 0.63 ± 0.28 (PET), (P 5 .78).
Conclusions. 82Rb-PET underestimates area at risk in patients with STEMI when compared
to SPECT and CMR. However, our findings suggest that PET imaging seems feasible when
assessing the clinical important parameters of final infarct size and myocardial salvage index,
although with great variability, in a selected STEMI population with large infarcts. These
findings should be confirmed in a larger population. (J Nucl Cardiol 2018;25:970–81.)
Key Words: Area at risk Æ final infarct size Æ myocardial salvage Æ rubidium-82 PET Æ
SPECT Æ cardiac magnetic resonance
Reprint requests: Adam Ali Ghotbi, MD, Department of Clinical Phy-
siology, NuclearMedicine& PET andCluster forMolecular Imaging,
Rigshospitalet and University of Copenhagen, Blegdamsvej 9, 2100
Copenhagen, Denmark; adamghotbi@gmail.com
1071-3581/$34.00
Copyright  2016 The Author(s). This article is published with open
access at Springerlink.com
970
Abbreviations
AAR Area at risk
AHA-17 American Heart Association 17-seg-
ment model
AMI Acute myocardial infarction
CMR Cardiac magnetic resonance
FIS Final infarct size
LV Left ventricle
MSI Myocardial salvage index
OSEM Ordered subsets expectation
maximization
pPCI Primary percutaneous coronary
intervention
PET Positron emission tomography
SPECT Single-photon emission computed
tomography
STEMI ST-segment elevation myocardial
infarction
82Rb Rubidium-82
ROI Region of interest
INTRODUCTION
Reperfusion therapy has significantly reduced mor-
tality in patients with acute myocardial infarction
(AMI). Consequently, large numbers of patients are
required to demonstrate further improvement in survival
with introduction of new treatment strategies.1 There-
fore, surrogate end-points for mortality are needed in
proof-of-concept trials assessing the efficacy of new
cardioprotective strategies. It has been shown that the
most critical determinant of prognosis and outcome in
patients with AMI is the final infarct size (FIS).2 The
area at risk (AAR), which is the initial endangered
myocardium, is a major determinant of the FIS,3 and
therefore recommended to measure in order to risk
stratify the patients.4 Measuring AAR and FIS enables
determining the myocardial salvage index (MSI), which
provides an indicator of therapeutic benefit.
Single-photon emission computed tomography
(SPECT) has been extensively validated in clinical
settings for the measurement of FIS and AAR, and is
considered gold standard in determining AAR.1,2,4–8 The
primary limitation of SPECT is that it is not easily
applied in the clinical setting. Therefore, other methods
have been developed such as cardiac magnetic reso-
nance imaging (CMR), ECG-based scoring systems, and
angiographic scores.9,10
CMR appears superior to SPECT in detection and
quantification of infarct size, and CMR can also be used
to assess AAR.1,11,12 However, CMR has additional
contraindications compared to SPECT, most of all the
presence of pacemakers and implantable defibrillators,
claustrophobia, and renal insufficiency.
Another promising modality for measuring AAR
and FIS is myocardial perfusion imaging with positron
emission tomography (PET). Generator-based Rubid-
ium-82 (82Rb) has now eased the access to myocardial
perfusion with PET.13 Post-reperfusion imaging to
depict AAR with PET might be feasible since ische-
mia/reperfusion injury entails a decrease in the sodium-
potassium pump activity, hence limiting the incorpora-
tion of 82Rb in the myocytes in the endangered
myocardium.14,15 With higher spatial and temporal
resolution than SPECT and considerably shorter scan
time than CMR and no contraindication, PET could
provide accurate and reproducible measurements of
AAR and FIS.
The aim of this prospective study was therefore to
compare rest 82Rb-PET myocardial perfusion imaging to
SPECT and CMR in terms of measurements of AAR,
FIS, and MSI in patients with ST-segment elevation
myocardial infarction (STEMI) undergoing reperfusion
with primary percutaneous coronary intervention
(pPCI).
METHODS
Study group
The study design is outlined in Figure 1. Twelve patients
(11 male, median [interquartile range, IQR] age 58 (53;
68) years) with STEMI were enrolled. Duration from onset of
symptoms to arrival at the catheterization laboratory was less
than 12 hours. STEMI was defined as ST-segment elevation in
2 contiguous electrocardiographic (ECG) leads of[0.1 mV in
V4 - V6 or leads II, III, and aVR, or[ 0.2 mV in lead V1 -
V3. Patient enrolment only took place during the opening hours
of the Department of Nuclear Medicine. Exclusion criteria
were cardiogenic shock, previous myocardial infarction, stent
thrombosis, unconsciousness, or previous coronary artery
bypass grafting.
Coronary angiography was performed to confirm occlu-
sion in the infarct-related artery, and pPCI was performed
according to local standard procedures.
All patients triaged for pPCI were pre-treated with
standard therapy, including oxygen, sublingual nitroglycerin,
aspirin (300 mg), prasugrel (60 mg), and heparin (10,000 units
i.v.), and treated during the procedure with bivalirudin if not
contraindicated.
Ethics
The independent local ethics committee approved this
study, protocol no: H-4-2010-054. All patients received oral
See related editorial, pp. 982–985
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and written information, and written consent was obtained
from all patients before inclusion in compliance with the
Declaration of Helsinki.
SPECT acquisition
Prior to opening of the occluded vessel(s), patients
received a 700 MBq i.v. injection of 99mTc-Sestamibi.
Myocardial SPECT imaging was performed within 1-4 hours
after pPCI to visualize AAR. Patients were in supine
position with continuous ECG monitoring. Images were
acquired using a dual-head gamma camera with low-energy,
high-resolution collimators, (Philips Precedence 16 Slice
SPECT/CT, Eindhoven, The Netherlands) in an ECG-gated
64-by-64 matrix with 32 projections, acquisition time of
20 seconds per projection, and 8 frames per cardiac cycle
with a 20% window centered on the 140 keV photopeak of
99mTc. For attenuation correction, a low-dose computed
tomography scan (CT) was acquired. Processing and recon-
struction of SPECT images were conducted by iterative
ordered subsets expectation maximization (OSEM) algo-
rithm; 2 iterations, 10 subsets. The early SPECT imaging
was considered as the gold standard of AAR estima-
tion.5,16,17 A follow-up scan was conducted in a similar
manner 3 months later to assess FIS. MSI was calculated as
(AAR - FIS)/AAR.
Figure 1. Study flow diagram. pPCI primary percutaneous coronary intervention; SPECT single
photon mission computed tomography; PET positron emission tomography; CMR cardiac magnetic
resonance.
972 Ghotbi et al Journal of Nuclear Cardiology
Ischemic area at risk May/June 2018
CMR acquisition
Patients were screened for contraindications, and if none
existed, cardiac imaging was performed on a 1.5 T scanner
(Avanto, Siemens, Erlangen, Germany) with the use of a 6-
channel body array coil. CMR was conducted twice: subacute
and at 3-month follow-up. The subacute imaging was not
performed earlier than 12 hours after pPCI to allow for
development of myocardial oedema, and\ 3 days after pPCI.
Patients were scanned in a supine position, and images were
obtained at end-expiratory breath hold with ECG gating. To
visualize edema and determine AAR (subacute scan only),
multiple T2-weighted short tau inversion recovery sequences
(slice thickness, 8 mm; field of view, 300-360 mm; inversion
time, 180 ms; repetition time, 2 R-R intervals; echo time,
65 ms; slice gap, 0 mm) were applied in short-axis image
plane from base to apex covering the entire left ventricle (LV).
FIS was assessed at follow-up scan 10 minutes after the
administration of diethylenetriamine pentaacetic acid (0.1 mL/
kg; Gadovist, Bayer Schering, Berlin, Germany). An ECG-
triggered enhancement inversion recovery was utilized (slice
thickness, 8 mm; field of view, 300-360 mm; echo time,
1.4 ms, slice gap 0 mm). The LV was covered from base to
apex in short-axis image plan: by adjusting the inversion time,
the signal from the normal myocardium was nulled for each
slice. The follow-up CMR FIS was, in this study, considered as
gold standard method to estimate this parameter.5,18,19
PET acquisition
Approximately, 24 h after 99mTc injection, a rest cardiac
PET imaging was performed using a Siemens Biograph mCT/
PET 64-slice scanner (Siemens Medical, Knoxville, USA.)
First, a low-dose CT scan was acquired for attenuation
correction. Following i.v. administration of approximately
1,100 MBq of 82Rb (Cardiogen•82, Bracco Diagnostics Inc.,
Princeton, NJ, USA), dynamic and gated (8 frames per cardiac
cycle) data acquisition was performed in 3D list mode for
7 min at rest. Images were reconstructed into 21 frames
(12 9 10, 3 9 20, 6 9 30 seconds) with attenuation, scatter,
and decay corrections using 3D OSEM, Gaussian filtering with
10 mm full width at half maximum. The follow-up scan was
carried out 3 months later with similar settings to gauge FIS.
SPECT and PET image analysis
Subacute and follow-up semi-quantitative data from
SPECT and PET were both processed and analyzed semi-
automatically in Cedars QPS/QGS software (v. 2012, Cedars
Sinai, Los Angeles, CA, USA). Two experienced observers
assessed the accuracy of slice alignments in the ventricular
planes and intervened if necessary (blinded to CMR data). The
perfusion defects (and thus AAR and FIS) were subsequently
quantified in (1) the total LV, and (2) in each of the 17
segments according to the American Heart Association (AHA)
17-segment model.20 The magnitude of the rest perfusion
defects (that was equal to assumed AAR in the subacute and
FIS in the follow-up scan) was determined automatically by
comparing the polar plot of a patient to that of the normal
database on a pixel-by-pixel basis. A 2.5 standard deviation
cut-off was used to define whether a pixel count fell below a
normal value. The normal limit approach has previously been
used to estimate AAR and FIS.21–23 However, we also
estimated AAR in SPECT images using the threshold approach
of 50% of peak counts and compared it to the results of the
normal limit method.
The cut-off value of 2.5 standard deviations to define
abnormality on the 82Rb PET uptake are derived from SPECT
guidelines, but has not been validated for AAR assessment
with 82Rb PET. Consequently, percentage of perfusion defect
from PET in each of the 17 segments was compared to the gold
standard of SPECT AAR in the segments to obtain optimal cut-
off values with receiver operating characteristics (ROC)
analysis.
CMR image analysis
Endocardial and epicardial contours were manually traced
in all short-axis images by two experienced observers (blinded
to SPECT and PET data). A region of interest (ROI) was
drawn in the normal (remote) myocardium, and AAR was
defined as hyperintensive myocardium 2 standard deviations
above the mean value in ROI on the T2-weighted images.7
Hypointensive areas within the AAR (e.g., hemorrhage or
microvascular obstruction) were considered as part of the
AAR. Scattered areas of hyperintensity in the normal myo-
cardium were manually excluded. AAR was calculated as
percent of the LV volume. Identical to the subacute scan, the
endo- and epicardial contours were manually traced at the
follow-up images, and a ROI was placed in the normal
myocardium. FIS was defined as hyperintensive myocardium 5
standard deviations above the mean value in ROI.7 FIS was
calculated as percent of the LV volume. The analyses were
performed with CVI42 software, v. 4.0 (Circle Cardiovascular
Imaging Inc., Calgary, Canada).
Statistical analysis
Descriptive patient parameters are presented as median
with IQR. Outcome variables are presented as mean ± stan-
dard deviation (SD) and categorical variables as frequencies or
percent (%). All variables were tested with normality plots. To
compare the three modalities, non-parametric Friedman test
was used, and whenever a significant difference was observed,
Dunn’s test for correction of multiple comparisons was
performed. Correlation between any two modalities was
examined by Spearman’s correlation. In addition, Bland-
Altman test was performed to evaluate the agreement between
SPECT, CMR, and PET. ROC analyses were generated in
order to acquire the ideal cut-off values of PET parameters vs
SPECT (‘‘gold standard’’). Accuracy, sensitivity, specificity,
positive predictive value (PPV), and negative predictive value
(NPV) were calculated for PET AHA 17-perfusion defects. A
P value\.05 was considered significant. All statistical anal-
yses were performed using SPSS version 19 (IBM, Chicago,
IL, USA).
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Statistical considerations
In a previous study comparing CMR and SPECT, AAR
and FIS have been presented as 30 ± 19% and 15 ± 17% of
the LV with SPECT and 28 ± 15% and 16 ± 14% of LV
with CMR (mean ± SD), respectively.16 We estimated the
sample size in a pre-trial power calculation (a = type I error
at 5% and 80% power (1 - b)) by two methods with the
following:
(1) Sample size by correlation coefficient: A correlation of no
less than r = 0.75 would be acceptable; hence, a sample
size of 11 paired patients was required.
(2) Sample size for paired difference in mean: Prior investi-
gations of SPECT and CMR claim a SD of 8-12 for mean
difference. Thus, an acceptable mean difference of 8 ± 8%
would result in a sample requirement of 10. To account for
loss of patients to follow-up, 12 patients were included in
the comparison of SPECT, PET, and CMR in regard to
AAR and FIS.
RESULTS
Eleven of the initial twelve patients were included
in the AAR analysis (one patient excluded due to
previous infarction) and ten patients were included in
the follow-up analysis (one patient died during follow-
up) (Figure 1). Baseline characteristics are shown in
Table 1.
Median AAR estimation in SPECT images was not
significantly different when measured with the threshold
or the normal limit approach. Bias was -1.49 ± 12.8%,
95% limits of agreement were -26.5% to 23.5% (results
not shown).
SPECT, CMR, and PET comparison
SPECT, CMR, and PET were performed
2.2 ± 0.3 h, 34 ± 8 h, and 32 ± 7 h after 99mTc-Ses-
tamibi injection and pPCI, respectively. In SPECT
imaging, mean AAR estimate was 35.2 ± 16.6%, and in
CMR, AAR was 34.7 ± 11.3%, while in PET, AAR
estimate was 28.1 ± 16.1% of the LV, resulting in a
significant difference between the three modalities
(P = .04). Post hoc paired tests revealed no significant
difference between SPECT and CMR AAR (P = .75),
whereas PET AAR estimate was significantly smaller
compared to the other two modalities (P = .02 vs
SPECT, P = .04 vs CMR). The 95% limits of agree-
ment were -9.2 to 23.5% (SPECT vs PET), -19.0% to
19.3% (SPECT vs CMR), and -13.9% to 27.43% (CMR
vs PET). SPECT correlated well in regard to AAR with
PET and CMR (Spearman’s rho rs = 0.86, 95% CI 0.51-
0.96, P\ .001; rs = 0.79, 95% CI 0.35-0.95; P\ .005,
respectively) (Figure 2A).
Despite the overall good agreement between the 3
modalities, there were substantial differences in indi-
vidual cases.
Follow-up SPECT, CMR, and PET were performed
on the same day on average 95 ± 6 days after the initial
pPCI treatment. Mean FIS estimate was 12.3 ± 15.4%,
13.7 ± 10.4%, and 11.9 ± 14.6% of LV in SPECT,
Table 1. Baseline characteristics
Patients
(n 5 11)
Age (years) 58 (53; 68)
Male 10 (91%)
Hypertension 2 (18%)
Hypercholesterolemia 2 (18%)
Total cholesterol, mmol/L 4.9 (4.1; 5.3)
Diabetes 0
Smoking
Non 5 (46%)
Active 2 (18%)
Ex 4 (36%)
Family history of premature CAD 4 (36%)
Peripheral Arterial Disease 0
Infarct location
LAD 6 (55%)
RCA 5 (45%)
LCX 0
TIMI flow prior to pPCI
0 5 (46%)
1 3 (27%)
2 2 (18%)
3 1 (9%)
TIMI flow post-pPCI
0 0
1 0
2 3 (27%)
3 8 (73%)
Peak Troponin T (ng/mL) 3710 (1450; 5850)
Peak CK-MB (U/I) 200 (70.9; 320)
Left Ventricle Ejection Fraction
post-pPCI (echocardiography)
(%)
40 (35; 50)
Time from symptom-onset to
PCI (min)
175 (125; 300)
Time door-to-PCI (min) 27 (24; 29)
Values are median (interquartile range) or n (%)
CAD, coronary artery disease; LAD, left anterior descending
artery; RCA, right coronary artery; LCX, left circumflex artery;
TIMI, thrombolysis in myocardial infarction; CK-MB, creatine
kinase myocardial band; pPCI, primary percutaneous
intervention
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CMR, and PET imaging, respectively, P = .72 for
difference. 95% limits of agreement were -11.4% to
13.8% (SPECT vs PET), -20.1 to 19.9% (SPECT vs
CMR), and -16.9% to 14.3% (CMR vs PET). Figure 2B
depicts the agreement and correlation for follow-up
measurements. MSI was comparable: 0.64 ± 0.33
(SPECT), 0.63 ± 0.28 (PET), and 0.65 ± 0.20 (CMR)
with no statistically significant difference (P = .78)
between the modalities; however, the correlations were
weak and non-significant between CMR and the other
modalities. Correlations, agreements, and MS indices
are reported in Figure 2C and Table 2, respectively.
Optimization of PET for accurate AAR
assessment
A ROC curve was created to assess the discrimi-
natory ability of PET-derived perfusion to detect SPECT
AAR. The accuracy of PET AAR could be optimized by
changing the segmental cut-off value of perfusion deficit
to 35%, which resulted in a sensitivity of 85%, speci-
ficity of 94%, PPV of 87%, NPV of 93%, and accuracy
of 91%. Area under the ROC curve was 0.92 (CI: 0.87-
0.97, P\ 0.0001).
DISCUSSION
To our knowledge, the present study is the first to
compare and evaluate the use of PET to measure AAR,
FIS, and MSI to the current gold standard methods of
SPECT and CMR. Despite differences in tracer prop-
erty, imaging technique, reconstruction algorithms, and
intervening revascularization, the three modalities cor-
related well in regard to AAR and FIS. However, the
limits of agreement were fairly large, and PET under-
estimated the AAR with approximately 7% compared to
SPECT. Our data suggest that this difference could be
corrected for by applying new PET cut-off values to
distinguish normal from hypoperfused segments. How-
ever, this cut-off is exploratory and needs to be verified
in a separate cohort. Overall, the clinical relevant
parameters of FIS and MSI were comparable between
the modalities.
It is of great importance to establish the AAR when
evaluating the efficacy of new infarct-limiting strategies
because the variation in the endangered area is great
even with similar segments with coronary occlusion.24
However, the concept and definition of AAR has
recently gained attention since no clear standardized
measurement exists.25,26 The original SPECT-derived
AAR measurements are based on pioneer studies from
late 1980s and early 1990s.8,27 These studies used
reconstruction techniques that are different form current
practice (i.e., filtered back projection without AC).
Recently, the T2-weighted method of delineating AAR
by CMR has come under criticism. Kim et al. argue that
the developed edema does not depict AAR but rather the
infarct size.28 Therefore, the concept of ‘‘gold standard’’
must be viewed with caution.29
Not surprisingly, the estimated AAR was signifi-
cantly smaller in PET imaging compared to SPECT and
CMR. SPECT and PET imaging assess perfusion with
different approaches. While 99mTc-Sestamibi is incor-
porated in the mitochondria of living myocytes, 82Rb
works as a potassium analogue and accumulates in the
myocytes via the Na?/K? ATPase.13 Furthermore,
fundamental differences in image acquisition and tech-
nology between SPECT and PET could, at least in part,
explain the differences in measured AAR. Previously,
different cut-off values of 50%30 and 60%8 of peak
counts have been proposed as the optimal cut-off to
depict AAR with SPECT. We choose a similar cut-off
value for SPECT and PET, 2.5 SD (&50%). However,
we find that an optimization of the cut-off values
between normal and hypoperfused myocardium is pos-
sible with PET. Although earlier papers have used the
normal limits approach to measure the AAR,21–23 the
method has not been vastly validated and could pose a
limitation.
Previous papers16,17 have reported smaller AAR
estimations by SPECT and CMR than our results. This
could potentially result in an overestimation of MSI. The
discrepancies could be the result of our small sample
population and selection bias. However, other studies
report comparable CMR-derived AAR estimations and
standard deviations to our results.31,32
It is somewhat counterintuitive that 82Rb-PET after
revascularization can assess the AAR. The potential
mechanism is unknown, but it is our hypothesis that
although the patency of an epicardial artery is re-
established, the ischemia/reperfusion injury may entail
microvascular impairment33 and depress the myocytes
Na?/K? ATPase activity.15,34 This damage to the
coronary microcirculation and the decrease in activity
in the sodium-potassium pump could explain the defects
seen subsequent to pPCI and enables 82Rb to visualize
AAR. In addition, the contrast between previously
jeopardized myocardium (AAR) and normal myocar-
dium after AMI seems enhanced by findings of
hyperaemia in the normal myocardium only.35,36 It
may be speculated that the decreased flow in the infarct-
related territory, compared to normal myocardium, is a
manifestation of microvascular obstruction/dysfunction
due to edema, clotting by blood components, and
endothelial disruption.37
Serial 99mTc SPECT imaging before and 18-48 h
after reperfusion therapy has previously been conducted
to demonstrate patient infarct-related artery when
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treated with thrombolytic agents.38–40 They reported
marked reductions in the extent of defect size (9%-50%)
between initial and follow-up imaging at 18-48 hours. It
has been suggested that the uptake of 99mTc after
reperfusion not merely depends on blood flow but also
the viability of the myocardium, thus reflecting the
degree of necrosis and salvage.41 It seems that SPECT
imaging at 18-48 hours measures AAR with a large
difference compared to pre-reperfusion assessment.
FIS is considered an important surrogate marker of
mortality and morbidity,6 and in many studies used as
primary end-point.22,42,43 Median FIS was not signifi-
cantly different when compared across the three
modalities. PET had minor bias and a very close
correlation with CMR. Despite the good agreement
between PET and CMR, substantial differences and
variability exist regarding the measurement of FIS,
which is demonstrated by the large limits of agreement.
Hadamitzky et al. showed similar large limits of
agreement when comparing SPECT to CMR.16 It would
be important if PET could estimate FIS comparable to
CMR, since a considerable number of patients are
unable to undergo CMR due to claustrophobia or other
contraindications.44
MSI is of clinical importance, since it conveys a
measurement of the potential benefit patients with AMI
Figure 2. (A) Area at risk correlations, Bland-Altman plots. (B) Final infarct size correlations,
Bland-Altman plots. (C) Myocardial salvage index correlations, Bland-Altman plots. rs Spearman’s
rho; SD standard deviation. Other abbreviations as in Fig. 1.
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experience from a certain reperfusion therapy.45,46 MSI
derived from the three modalities showed good congru-
ence. It is noteworthy that in some studies,43,45 only MSI
is a predictor of mortality and not myocardial salvage
alone. Recently, a study demonstrated that MSI by CMR
could reduce sample size in cardioprotection trials by
46% compared to myocardial infarction alone.47 How-
ever, the variability of MSI in our study was notable,
although comparable to the results of Hadamitzky
et al.16 Moreover, the correlations between the modal-
ities were not significant when comparing CMR with
PET or SPECT.
The financial aspects of the three modalities are
beyond the scope of this paper, but the expenses
associated with each scanner and the monthly cost of
an 82Rb generator should be taken into consideration.
LIMITATIONS
Due to the comprehensive study protocol, the
number of patients included was small and may impact
our conclusions due to risk of type II error. Furthermore,
we lack stress-induced PET imaging, which could have
provided additional information regarding coronary flow
reserve. We did not perform stress imaging due to the
proximity to the index STEMI of concern for adverse
effects. Previous perfusion studies using N-13 ammonia
early after MI did not reveal any significant difference in
infarct size under resting and adenosine conditions,
hence questioning the absolute need for stress
imaging.48
AAR and FIS estimations in SPECT and PET
imaging are dependent on the software applications in
use, and there is no consensus on which application to
Figure 2. continued.
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Figure 2. continued.
Table 2. SPECT, CMR and PET results
SPECT CMR PET P value (Friedman)
Time from 99mTc tracer inj. to (h) 2.2 ± 0.3 34.5 ± 8.5 32.4 ± 24.4 0.02
Area at risk, % of LV 35.2 ± 16.6 34.7 ± 11.3 28.1 ± 16.1§ 0.03
Final infarct size, % of LV 12.3 ± 15.4 13.7 ± 10.4 11.9 ± 14.6 0.72
Myocardial salvage index 0.64 ± 0.33 0.65 ± 0.20 0.63 ± 0.28 0.78
Values are mean ± SD
99mTc, technetium-99m; LV, left ventricle; Salvage index, (AAR-FIS)/AAR; AAR, area at risk; FIS, final infarct size
 P\ .05 compared to SPECT
§ P\ .05 compared to CMR
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use.29 The normal limit approach to estimate AAR
and FIS in SPECT has not been used on regular basis
and therefore not extensively validated, albeit some
papers have previously applied this method.21–23
Furthermore, no standard technique is widely
accepted for CMR quantification of AAR and FIS
on late gadolinium and T2-weighted images, respec-
tively.49 Thus, lack of a well-defined, explicit ‘‘gold
standard’’ reference for both AAR and FIS could be
argued to be a limitation.
CONCLUSION
The present study suggests that determining FIS and
MSI is feasible with 82Rb-PET imaging shortly after
pPCI and at follow-up in a STEMI population with
larger infarcts, albeit a vast variability hampers direct
transference of results between the modalities. In addi-
tion, PET underestimated AAR with 7% compared to
SPECT, but our data suggest that AAR assessment by
PET could be optimized with the use of new cut-off
values to define abnormality. These findings should be
confirmed and further optimized in a larger patient
STEMI population.
NEW KNOWLEDGE GAINED
82Rb-PET could potentially allow fast and reliable
estimation of FIS and MSI, which are important param-
eters in evaluating new reperfusion strategies. With
lower radiation than SPECT and no contraindication
compared to CMR, 82Rb-PET could be an alternative in
the post-infarction cardiac imaging toolbox.
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